[spacer.gif] APPENDIX D BIBLIOGRAPHY Abraira C, Colwell J, Nuttall F et al.
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial.
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.
Arch Intern Med 1997; 157 (2):181-8.
Abraira C, Colwell JA, Nuttall FQ et al.
Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM).
Results of the feasibility trial.
Veterans Affairs Cooperative Study in Type II Diabetes.
Diabetes Care 1995; 18 (8):1113-23.
Abraira C, Henderson WG, Colwell JA et al.
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes.
VA feasibility study on glycemic control and complications (VA CSDM).
Diabetes Care 1998; 21 (4):574-9.
Agardh E, Agardh CD, Koul S et al.
A four-year follow-up study on the incidence of diabetic retinopathy in older onset diabetes mellitus.
Diabet Med 1994; 11 (3):273-8.
Agurs-Collins TD, Kumanyika SK, Ten Have TR et al.
A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects.
Diabetes Care 1997; 20 (10):1503-11.
Ahroni JH. Teaching foot care creatively and successfully.
Diabetes Educ 1993; 19 (4):320-1, 3-4.
Alogna M. CDC Diabetes Control Programs--overview of diabetes patient education.
Diabetes Educ 1985; 10 (4):32-6, 57.
American College of Sports Medicine.
ACSM's guidelines for exercise testing and prescription.
5th ed. Baltimore, MD: Williams 
American Diabetes Association (ADA).
Census development conference on the diagnosis and management of nephropathy in patients with diabetes melllitus.
Diabetes Care 1994; 17:1357-61.
American Diabetes Association (ADA).
Clinical practice recommendations 2002.
Diabetes Care 2002; 25 Suppl 1:S1-147.
American Diabetes Association (ADA).
The First Step in Diabetes Meal Planning 1995a.
American Diabetes Association (ADA).
Management of dyslipidemia in adults with diabetes.
Diabetes Care 1999; 22 (Suppl 1):S56.
American Diabetes Association (ADA).
Meeting the Standards.
Standard 12.
National Standards for Diabetes Self-Management Education Program Recognition Application Manual.
Alexandria, VA 1998.
American Diabetes Association (ADA).
Position statement: diabetic nephropathy.
Diabetes Care 1997a; 20 (S1):S24-7.
American Diabetes Association (ADA).
Preventive foot care in people with diabetes.
Diabetes Care 2000; 23 Suppl 1:S55-6.
American Diabetes Association (ADA).
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
Diabetes Care 1997b; 20:1183-97.
American Diabetes Association (ADA).
Screening for type 2 diabetes.
Position statement.
Diabetes Care 1988; 21 (Suppl 1):S20-S2.
American Diabetes Association (ADA).
Standards of medical care for patients with diabetes mellitus.
Diabetes Care 1995; 18:8-15.
American Diabetes Association (ADA).
Standards of medical care for patients with diabetes mellitus.
Diabetes Care 1998; 21 (S1):S8, 23-31.
American Diabetes Association (ADA).
Standards of Medical Care for Patients with Diabetes Mellitus.
Diabetes Care 1999; 1999 (22):Suppl 1.
American Diabetes Association and The American Dietetic Association.
The first step in diabetes meal planning.
Alexandria, VA: American Diabetes Association.
American Diabetes Association Position Statement.
Implications of the diabetes control and complications trial.
1993.
American Diabetes Association: clinical practice recommendations 2002.
Diabetes Care 2002; 25 Suppl 1:S1-147.
Andersen S, Tarnow L, Rossing P et al.
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Kidney Int 2000; 57 (2):601-6.
Anderson JH, Jr., Brunelle RL, Keohane P et al.
Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus.
Multicenter Insulin Lispro Study Group.
Arch Intern Med 1997; 157 (11):1249-55.
Anderson RM, Funnell MM, Butler PM et al.
Patient empowerment.
Results of a randomized controlled trial.
Diabetes Care 1995; 18 (7):943-9.
Antiplatelet Trialists' Collaboration.
Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials.
Bmj 1994; 309 (6963):1215-7.
Arseneau DL, Mason AC, Wood OB et al.
A comparison of learning activity packages and classroom instruction for diet management of patients with non-insulin-dependent diabetes mellitus.
Diabetes Educ 1994; 20 (6):509-14.
Aubert RE, Herman WH, Waters J et al.
Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization.
A randomized, controlled trial.
Ann Intern Med 1998; 129 (8):605-12.
Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus.
A randomized, double-blind, placebo-controlled trial.
Ann Intern Med 1999; 131 (3):182-8.
Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national cholesterol policy.
Ann Intern Med 1996; 125 (6):502-6.
Babcock DE, Miller MA. Client education: theory 
St. Louis, MO: Mosby; 1994.
Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetes clinic.
Am J Med 1985; 78 (3):371-4.
Bakris GL, Copley JB, Vicknair N et al.
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
Kidney Int 1996; 50 (5):1641-50.
Bakris GL, Weir MR, DeQuattro V et al.
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Kidney Int 1998; 54 (4):1283-9.
Barth R, Campbell LV, Allen S et al.
Intensive education improves knowledge, compliance, and foot problems in type 2 diabetes.
Diabet Med 1991; 8 (2):111-7.
Bastyr EJ, 3rd, Johnson ME, Trautmann ME et al.
Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.
Clin Ther 1999; 21 (10):1703-14.
Bastyr EJ, 3rd, Stuart CA, Brodows RG et al.
Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c.
IOEZ Study Group.Diabetes Care 2000; 23 (9):1236-41.
Bayraktar M, Van Thiel DH, Adalar N.
A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Diabetes Care 1996; 19 (3):252-4.
Becerra JE, Khoury MJ, Cordero JF et al.
Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study.
Pediatrics 1990; 85 (1):1-9.
Bectron Dickinson Consumer Products: Getting Started-Controlling Low Blood Sugar Reactions, n/d.
Behounek BD, McGovern ME, Kassler-Taub KB et al.
A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia.
Pravastatin Multinational Study Group for Diabetes.
Clin Cardiol 1994; 17 (10):558-62.
Bennett PH, Haffner S, Kasiske BL et al.
Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation.
Am J Kidney Dis 1995; 25 (1):107-12.
Beri M, Klugman MR, Kohler JA et al.
Anterior ischemic optic neuropathy.
VII.
Incidence of bilaterality and various influencing factors.
Ophthalmology 1987; 94 (8):1020-8.
Birke JA, Sims DS.
The insensitive foot.
In: GC Hunt, editor, Physical Therapy of the Foot and Ankle.
New York: Churchill Livingstone; 1988; p. 133-68.
Bloomgarden ZT.
American Diabetes Association 60th Scientific Sessions, 2000: the diabetic foot.
Diabetes Care 2001; 24 (5):946-51.
Bode B, Weinstein R, Bell D, et al.
Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
Diabetes Care 2002; 25(3):439-444.
Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.
Diabetes Care 2001; 24(1):69-72.
Boehm BO, Home PD, Behrend C et al.
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
Diabet Med 2002; 19 (5):393-9.
Bonomi L, Marchini G, Marraffa M et al.
Prevalence of glaucoma and intraocular pressure distribution in a defined population.
The Egna-Neumarkt Study.
Ophthalmology 1998; 105 (2):209-15.
Boyko EJ, Ahroni JH, Smith DG et al.
Increased mortality associated with diabetic foot ulcer.
Diabet Med 1996; 13 (11):967-72.
Brenner BM, Cooper ME, de Zeeuw D et al.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 2001; 345 (12):861-9.
Bresnick GH, Mukamel DB, Dickinson JC et al.
A screening approach to the surveillance of patients with diabetes for the presence of vision-threatening retinopathy.
Ophthalmology 2000; 107 (1):19-24.
Brink S, Siminerio L, Hinnen-Hentzen D. Diabetes Education Goals.
Alexandria, VA: American Diabetes Association, Inc.; 1995.
63 p. Brodsky JW, Schneidler C. Diabetic foot infections.
Orthop Clin North Am 1991; 22 (3):473-89.
Brown GC, Magargal LE. Central retinal artery obstruction and visual acuity.
Ophthalmology 1982; 89 (1):14-9.
Brunelle BL, Llewelyn J, Anderson JH, Jr., et al.
Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes.
Diabetes Care 1998 21(10):1726-1731.
Buse JB, Gumbiner B, Mathias NP et al.
Troglitazone use in insulin-treated type 2 diabetic patients.
The Troglitazone Insulin Study Group.
Diabetes Care 1998; 21 (9):1455-61.
Byington RP, Furberg CD, Craven TE et al.
Isradipine in prediabetic hypertensive subjects.
Diabetes Care 1998; 21 (12):2103-10.
Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ et al.
Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment.
Diabete Metab 1995; 21 (4):256-60.
Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis.
Diabetes Metab Rev 1995; 11 Suppl 1:S57-62.
Campeau L, Knatterud L, Damanski M et al.
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
The Post Coronary Artery Bypass Graft Trial Investigators.
N Engl J Med 1997; 336 (3):153-62.
Canner PL, Berge KG, Wenger NK et al.
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
J Am Coll Cardiol 1986; 8 (6):1245-55.
Caputo GM, Cavanagh PR, Ulbrecht JS et al.
Assessment and management of foot disease in patients with diabetes.
N Engl J Med 1994; 331 (13):854-60.
Carrington AL, Abbott CA, Griffiths J et al.
Peripheral vascular and nerve function associated with lower limb amputation in people with and without diabetes.
Clin Sci (Lond) 2001; 101 (3):261-6.
Cavanagh PR, Sanders LJ, Sims DS, Jr.
The role of pressure distribution measurement in diabetic foot care.
Rehabilitation R
CDC Diabetes Cost-Effectiveness Study Group.
The cost-effectiveness of screening for type 2 diabetes.
Jama 1998; 280 (20):1757-63.
Charpentier G, Fleury F, Kabir M et al.
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
Diabet Med 2001; 18 (10):828-34.
Chen MS, Kao CS, Fu CC et al.
Incidence and progression of diabetic retinopathy among non-insulin-dependent diabetic subjects: a 4-year follow-up.
Int J Epidemiol 1995; 24 (4):787-95.
Chen TH, Yen MF, Tung TH.
A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus.
Diabetes Res Clin Pract 2001; 54 Suppl 1:S37-42.
Chiasson JL, Josse RG, Hunt JA et al.
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus.
A multicenter controlled clinical trial.
Ann Intern Med 1994; 121 (12):928-35.
Chiasson JL, Naditch L.
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Diabetes Care 2001; 24 (6):989-94.
Chilcott J, Tappenden P, Jones ML et al.
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Clin Ther 2001; 23 (11):1792-823; discussion 1.
Chow CC, Tsang LW, Sorensen JP et al.
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Diabetes Care 1995; 18 (3):307-14.
Ciavarella A, Di Mizio G, Stefoni S et al.
Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy.
Diabetes Care 1987; 10 (4):407-13.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
Nephron 1976; 16 (1):31-41.
Coggins CH, Dwyer JT, Greene T et al.
Serum lipid changes associated with modified protein diets: results from the feasibility phase of the Modification of Diet in Renal Disease Study.
Am J Kidney Dis 1994; 23 (4):514-23.
Collins R, Baigent C, Sandercock P et al.
Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials.
Antiplatelet Trialists' Collaboration.
Bmj 1994; 309 (6963):1215-7.
Conget I, Jansa M, Vidal M et al.
Effects of an individual intensive educational control program for insulin-dependent diabetic subjects with poor metabolic control.
Diabetes Res Clin Pract 1995; 27 (3):189-92.
Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Arch Intern Med 1994; 154 (21):2442-8.
Conte MS, Belkin M, Donaldson MC et al.
Femorotibial bypass for claudication: do results justify an aggressive approach? J Vasc Surg 1995; 21 (6):873-80; discussion 80-1.
Coonrod BA, Betschart J, Harris MI. Frequency and determinants of diabetes patient education among adults in the U.S. population.
Diabetes Care 1994; 17 (8):852-8.
Corabian P, Harstall C. Patient diabetes education in the management of adult type 2 diabetes.
Alberta Heritage Foundation for Medical Research, HA 23: Series A, Health Technology Assessment 2001.
Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care.
Diabetes and Acarbose Research Group.
Diabetes Res Clin Pract 1997; 38 (1):33-40.
Coster S, Gulliford MC, Seed PT et al.
Self-monitoring in Type 2 diabetes mellitus: a meta-analysis.
Diabet Med 2000; 17 (11):755-61.
Cousins L. Pregnancy complications among diabetic women: review 1965-1985.
Obstet Gynecol Surv 1987; 42 (3):140-9.
Curb JD, Pressel SL, Cutler JA et al.
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension.
Systolic Hypertension in the Elderly Program Cooperative Research Group.
Jama 1996; 276 (23):1886-92.
Currie IC, Wilson YG, Baird RN et al.
Treatment of intermittent claudication: the impact on quality of life.
Eur J Vasc Endovasc Surg 1995; 10 (3):356-61.
Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects.
Diabetes Reviews 1998; 6:89-131.
Danese MD, Powe NR, Sawin CT et al.
Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.
Jama 1996; 276 (4):285-92.
Dasbach EJ, Fryback DG, Newcomb PA et al.
Cost-effectiveness of strategies for detecting diabetic retinopathy.
Med Care 1991; 29 (1):20-39.
Davey P, Grainger D, MacMillan J, et al.
Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.
Clin Ther 1997; 19(4):656-674.
Davidson JK, Delcher HK, Englund A. Spin-off cost/benefits of expanded nutritional care.
J Am Diet Assoc 1979; 75 (3):250-7.
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.
Collaborative Group of the Primary Prevention Project.
Lancet 2001; 357 (9250):89-95.
DeFronzo RA, Goodman AM.
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus.
The Multicenter Metformin Study Group.
N Engl J Med 1995; 333 (9):541-9.
Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice.
The DCCT Research Group.
J Am Diet Assoc 1993; 93 (7):758-64, 67.
Demacker PN, Toenhake-Dijkstra H, de Rijke YB et al.
On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis? Clin Chem 1996; 42 (9):1491-4.
Diabetes Control and Complications (DCCT) Research Group.
Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.
Am J Cardiol 1995; 75 (14):894-903.
Diabetes Control and Complications (DCCT) Research Group.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med 1993; 329 (14):977-86.
Diabetes Control and Complications (DCCT) Research Group.
Epidemiology of severe hypoglycemia in the diabetes control and complications trial.
The DCCT Research Group.
Am J Med 1991; 90 (4):450-9.
Diabetes Control and Complications (DCCT) Research Group.
Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice.
The DCCT Research Group.
J Am Diet Assoc 1993; 93 (7):758-64, 67.
Diabetes Control and Complications Trial (DCCT) Research Group.
Hypoglycemia in the Diabetes Control and Complications Trial.
Diabetes 1997; 46 (2):271-86.
Diabetes Education Pilot Program Experience 1/1/83-6/30/83.
Blue Cross/Blue Shield of North Dakota Evaluation of the State of Maryland's Diabetes Care Program, Baltimore County Center for Health Program Development and Management.
University of Maryland, 1995.
Diabetes Quality Improvement Project (DQIP), a Federal/Private Sector Coalition.
Dibble CM, Kochenour NK, Worley RJ et al.
Effect of pregnancy on diabetic retinopathy.
Obstet Gynecol 1982; 59 (6):699-704.
Donahue RP, Orchard TJ.
Diabetes mellitus and macrovascular complications.
An epidemiological perspective.
Diabetes Care 1992; 15 (9):1141-55.
Downs JR, Clearfield M, Weis S et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
Air Force/Texas Coronary Atherosclerosis Prevention Study.
Jama 1998; 279 (20):1615-22.
Early Treatment Diabetic Retinopathy Study.
Aspirin effects on mortality and morbidity in patients with diabetes mellitus.
Early Treatment Diabetic Retinopathy Study report 14.
Jama 1992; 268 (10):1292-300.
Early Treatment Diabetic Retinopathy Study Research Group: Early Photocoagulation for diabetic retinopathy.
ETDRS Report 9.
Ophthamology 1991: 98:766-785.
Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM.
I. Model construction and assumptions.
Diabetes Care 1997; 20 (5):725-34.
Ebeling P, Teppo AM, Koistinen HA et al.
Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes.
Metabolism 2001; 50 (3):283-7.
Ebrahim S, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease.
The Cochrane Library, Issue 2.
Oxford: Update Software.
1999.
Eckman MH, Greenfield S, Mackey WC et al.
Foot infections in diabetic patients.
Decision and cost-effectiveness analyses.
Jama 1995; 273 (9):712-20.
Edelman D, White D, Henry RR. Intensive insulin therapy for patients with type 2 diabetes.
Current Opinion in Endocrinology and Diabetes 1995; 2:333-40.
Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies.
Am J Ophthalmol 1981; 91 (3):381-95.
Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.
Am J Cardiol 1995; 75 (14):894-903.
Einhorn D, Rendell M, Rosenzweig J et al.
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.
The Pioglitazone 027 Study Group.
Clin Ther 2000; 22 (12):1395-409.
Ellison GC, Rayman KM. Exemplars' experience of self-managing type 2 diabetes.
Diabetes Educ 1998; 24 (3):325-30.
Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes.
Diabetes Care 2000; 23 (10):1563-80.
Epstein M, Sowers JR. Diabetes mellitus and hypertension.
Hypertension 1992; 19 (5):403-18.
Estacio RO, Jeffers BW, Gifford N et al.
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
Diabetes Care 2000; 23 Suppl 2:B54-64.
Estacio RO, Jeffers BW, Hiatt WR et al.
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
N Engl J Med 1998; 338 (10):645-52.
Evanoff G, Thompson C, Brown J et al.
Prolonged dietary protein restriction in diabetic nephropathy.
Arch Intern Med 1989; 149 (5):1129-33.
Faas A, Schellevis FG, Van Eijk JT.
The efficacy of self-monitoring of blood glucose in NIDDM subjects.
A criteria-based literature review.
Diabetes Care 1997; 20 (9):1482-6.
Fain JA, Melkus GD. Nurse practitioner practice patterns based on standards of medical care for patients with diabetes.
Diabetes Care 1994; 17 (8):879-81.
FDA.
Available at http://www.fda.gov/cder/foi/label/2000/20986lbl.pdf 2002.
Feinglos MN, Thacker CH, English J et al.
Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Diabetes Care 1997; 20 (10):1539-42.
Feinglos MN, Thacker CR, Lobaugh B et al.
Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
Diabetes Res Clin Pract 1998; 39 (3):193-9.
Ferris FL, 3rd.
How effective are treatments for diabetic retinopathy? Jama 1993; 269 (10):1290-1.
Feste C. Empowerment: facilitation a path to responsible self-care.
Elkhart, IN: Miles, Inc., Diagnostics Division; 1991.
Field AE, Coakley EH, Must A et al.
Impact of overweight on the risk of developing common chronic diseases during a 10-year period.
Arch Intern Med 2001; 161 (13):1581-6.
Fonseca V, Rosenstock J, Patwardhan R et al.
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Jama 2000; 283 (13):1695-702.
Franz MJ, editor A core curriculum for diabetes education, 4th edition.
Chicago: American Association of Diabetes Educators; 2001.
Franz MJ, Monk A, Barry B et al.
Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial.
J Am Diet Assoc 1995; 95 (9):1009-17.
Franz MJ, Splett PL, Monk A et al.
Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus.
J Am Diet Assoc 1995; 95 (9):1018-24.
Frick MH, Elo O, Haapa K et al.
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
N Engl J Med 1987; 317 (20):1237-45.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Clin Chem 1972; 18 (6):499-502.
Fritsche A, Schmulling RM, Haring HU et al.
Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Acta Diabetol 2000; 37 (1):13-8.
Fuhrmann K, Reiher H, Semmler K et al.
Prevention of congenital malformations in infants of insulin-dependent diabetic mothers.
Diabetes Care 1983; 6 (3):219-23.
Funnell MM, Haas LB. National Standards for Diabetes Self-Management Education Programs.
Diabetes Care 1995; 18 (1):100-16.
Gaede P, Vedel P, Parving HH et al.
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.
Lancet 1999; 353 (9153):617-22.
Gall MA, Rossing P, Skott P et al.
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 1991; 34 (9):655-61.
Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice.
Bmj 1997; 314 (7085):964-7.
Garcia R, Suarez R. Diabetes education in the elderly: a 5-year follow-up of an interactive approach.
Patient Educ Couns 1996; 29 (1):87-97.
Gentile S, Turco S, Guarino G et al.
Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.
Diabetes Obes Metab 2001; 3 (1):33-40.
Gerich JE. Novel insulins: expanding options in diabetes management.
Am J Med 2002; 113(4):308-316.
Giacalone VF. Phenol matricectomy in patients with diabetes.
J Foot Ankle Surg 1997; 36 (4):264-7; discussion 328.
Ginsberg JM, Chang BS, Matarese RA et al.
Use of single voided urine samples to estimate quantitative proteinuria.
N Engl J Med 1983; 309 (25):1543-6.
Ginsburg LH, Aiello LM. Diabetic retinopathy: classification, progression, and management.
Focal Points.
Clinical Modules for Ophthalmologist 1993; 11 (7):1-14.
Giugliano D, Quatraro A, Consoli G et al.
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Eur J Clin Pharmacol 1993; 44 (2):107-12.
Glasgow RE, Toobert DJ, Hampson SE et al.
Improving self-care among older patients with type II diabetes: the "Sixty Something..."
Study.
Patient Educ Couns 1992; 19 (1):61-74.
Glimepiride for NIDDM.
Med Lett Drugs Ther 1996; 38 (975):47-8.
Golay A, Guillet-Dauphine N, Fendel A et al.
The insulin-sparing effect of metformin in insulin-treated diabetic patients.
Diabetes Metab Rev 1995; 11 Suppl 1:S63-7.
Goldberg RB, Einhorn D, Lucas CP et al.
A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Diabetes Care 1998; 21 (11):1897-903.
Goodkin G. Mortality factors in diabetes.
A 20 year mortality study.
J Occup Med 1975; 17 (11):716-21.
Gordon DJ, Probstfield JL, Garrison RJ et al.
High-density lipoprotein cholesterol and cardiovascular disease.
Four prospective American studies.
Circulation 1989; 79 (1):8-15.
Gress TW, Nieto FJ, Shahar E et al.
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.
Atherosclerosis Risk in Communities Study.
N Engl J Med 2000; 342 (13):905-12.
Grundy SM. Statin trials and goals of cholesterol-lowering therapy.
Circulation 1998; 97 (15):1436-9.
Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults.
American College of Physicians.
Part 1.
Ann Intern Med 1996; 124 (5):515-7.
Guidelines Subcommittee.
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.
Guidelines Subcommittee.
J Hypertens 1999; 17 (2):151-83.
Guvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Acta Diabetol 1999; 36 (1-2):93-7.
Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease.
Am J Cardiol 1999; 83 (9B):17F-21F.
Haffner SM, Fong D, Stern MP et al.
Diabetic retinopathy in Mexican Americans and non-Hispanic whites.
Diabetes 1988; 37 (7):878-84.
Haffner SM, Lehto S, Ronnemaa T et al.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med 1998; 339 (4):229-34.
Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
Diabetes Res Clin Pract 2000; 50 (1):49-56.
Hamman RF, Mayer EJ, Moo-Young GA et al.
Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM.
San Luis Valley Diabetes Study.
Diabetes 1989; 38 (10):1231-7.
Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, et al.
Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study.
The Study Group for the Development of Pump Therapy in Diabetes.
Diabetes Care 2000; 23(9):1232-1235.
Hanefeld M, Fischer S, Schulze J et al.
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Diabetes Care 1991; 14 (8):732-7.
Hansen HP, Gaede PH, Jensen BR et al.
Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria.
Diabetes Care 2000; 23 (12):1742-5.
Hansson L, Zanchetti A, Carruthers SG et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
HOT Study Group.
Lancet 1998; 351 (9118):1755-62.
Harris M. Chapter 2 Classification, Diagnostic Criteria and Screening for Diabetes.
In: M Harris, editor, Diabetes in America, 2nd edition.
Bethesda, MD; 1995a.
Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM).
Clin Invest Med 1995b; 18 (4):231-9.
Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes.
Diabetes Care 2001; 24 (6):979-82.
Hasslacher C. Hypertension as a risk factor in non-insulin-dependent diabetes mellitus: how far should blood pressure be reduced? J Diabetes Complications 1997; 11 (2):90-1.
Haupt E, Knick B, Koschinsky T et al.
Oral antidiabetic combination therapy with sulphonylureas and metformin.
Diabete Metab 1991; 17 (1 Pt 2):224-31.
Hebel SK, editor Drug Facts and Comparisons St. Louis: Facts and Comparisons, Inc.; 1998.
Hemachandra A, Ellis D, Lloyd CE et al.
The influence of pregnancy on IDDM complications.
Diabetes Care 1995; 18 (7):950-4.
Henricsson M, Nilsson A, Janzon L et al.
The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus.
Diabet Med 1997; 14 (2):123-31.
Hermann LS, Kalen J, Katzman P et al.
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.
Diabetes Obes Metab 2001; 3 (6):428-34.
Hermann LS, Schersten B, Bitzen PO et al.
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations.
A double-blind controlled study.
Diabetes Care 1994; 17 (10):1100-9.
Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients.
The Essen Study.
Diabetes Care 1994; 17 (6):561-6.
Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Am J Med 1997; 103 (6):483-90.
Holewski JJ, Stess RM, Graf PM et al.
Aesthesiometry: quantification of cutaneous pressure sensation in diabetic peripheral neuropathy.
J Rehabil Res Dev 1988; 25 (2):1-10.
Holler H, Pastors J. Diabetes medical nutrition therapy.
American Dietetic Association, American Diabetes Association 1997.
Holman RR, Cull CA, Turner RC.
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
Diabetes Care 1999; 22 (6):960-4.
Home PD, Lindholm A, Hylleberg B et al.
Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients.
UK Insulin Aspart Study Group.
Diabetes Care 1998; 21 (11):1904-9.
Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
Diabet Med 2000; 17 (11):762-70.
HOPE.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Heart Outcomes Prevention Evaluation Study Investigators.
Lancet 2000; 355 (9200):253-9.
Horton ES, Clinkingbeard C, Gatlin M et al.
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Diabetes Care 2000; 23 (11):1660-5.
Horton ES, Whitehouse F, Ghazzi MN et al.
Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes.
The Troglitazone Study Group.
Diabetes Care 1998; 21 (9):1462-9.
Humphrey LL, Ballard DJ, Frohnert PP et al.
Chronic renal failure in non-insulin-dependent diabetes mellitus.
A population-based study in Rochester, Minnesota.
Ann Intern Med 1989; 111 (10):788-96.
Hunninghake DB, Miller VT, LaRosa JC et al.
Long-term treatment of hypercholesterolemia with dietary fiber.
Am J Med 1994; 97 (6):504-8.
Inzucchi SE.
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Jama 2002; 287 (3):360-72.
Inzucchi SE, Maggs DG, Spollett GR et al.
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
N Engl J Med 1998; 338 (13):867-72.
Iwamoto Y, Kosaka K, Kuzuya T et al.
Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Diabet Med 1996; 13 (4):365-70.
Jaber LA, Halapy H, Fernet M et al.
Evaluation of a pharmaceutical care model on diabetes management.
Ann Pharmacother 1996; 30 (3):238-43.
Jacobson JM, O'Rourke PJ, Wolf AE. Impact of a diabetes teaching program on health care trends in an Air Force Medical Center.
Mil Med 1983; 148 (1):46-7.
Javitt JC, Aiello LP.
Cost-effectiveness of detecting and treating diabetic retinopathy.
Ann Intern Med 1996; 124 (1 Pt 2):164-9.
Javitt JC, Aiello LP, Chiang Y et al.
Preventive eye care in people with diabetes is cost-saving to the federal government.
Implications for health-care reform.
Diabetes Care 1994; 17 (8):909-17.
Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics.
Ophthalmology 1989; 96 (2):255-64.
JNC-VI 1997.
See sixth report of the joint national committee on detection, evaluation and treatment of high blood pressure.
1997.
Johansen K. Efficacy of metformin in the treatment of NIDDM.
Meta-analysis.
Diabetes Care 1999; 22 (1):33-7.
Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes.
A meta-analysis of the randomized placebo-controlled trials.
Arch Intern Med 1996; 156 (3):259-64.
Johnston PS, Feig PU, Coniff RF et al.
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Diabetes Care 1998a; 21 (3):409-15.
Johnston PS, Feig PU, Coniff RF et al.
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Diabetes Care 1998b; 21 (3):416-22.
Kasiske BL, Kalil RS, Ma JZ et al.
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.
Ann Intern Med 1993; 118 (2):129-38.
Kawazu S, Tomono S, Shimizu M et al.
The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus.
The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study.
J Diabetes Complications 1994; 8 (1):13-7.
Kelley DE, Bidot P, Freedman Z et al.
Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Diabetes Care 1998; 21 (12):2056-61.
K/DOQI CPG on Chronic Kidney Diseases.
AJKD 2002;39(2): Suppl.1.
Kim HK, Kim CH, Kim SW et al.
Development and progression of diabetic retinopathy in Koreans with NIDDM.
Diabetes Care 1998; 21 (1):134-8.
Kipnes MS, Krosnick A, Rendell MS et al.
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Am J Med 2001; 111 (1):10-7.
Kirk JK, Pearce KA, Michielutte R et al.
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes? J Fam Pract 1999; 48 (11):879-82.
Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes.
The Beaver Dam Eye Study.
Ophthalmology 1994; 101 (7):1173-7.
Klein BE, Klein R, Wang Q et al.
Older-onset diabetes and lens opacities.
The Beaver Dam Eye Study.
Ophthalmic Epidemiol 1995; 2 (1):49-55.
Klein BEK, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy.
Diabetes Care 1990; 13 (1):34-40.
Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes.
Diabetes Care 1995; 18 (2):258-68.
Klein R, Klein BE, Moss SE et al.
The Wisconsin Epidemiologic Study of diabetic retinopathy.
XIV.
Ten-year incidence and progression of diabetic retinopathy.
Arch Ophthalmol 1994; 112 (9):1217-28.
Klein R, Klein BE, Moss SE et al.
The Wisconsin epidemiologic study of diabetic retinopathy.
II.
Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.
Arch Ophthalmol 1984a; 102 (4):520-6.
Klein R, Klein BE, Moss SE et al.
The Wisconsin epidemiologic study of diabetic retinopathy.
III.
Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.
Arch Ophthalmol 1984b; 102 (4):527-32.
Klein R, Klein BE, Moss SE et al.
The Beaver Dam Eye Study.
Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus.
Ophthalmology 1992a; 99 (1):58-62.
Klein R, Klein BEK.
Vision disorders in diabetes.
In: National Diabetes Data Group, editor, Diabetes in America.
2nd edn. Bethesda, MD: National Institutes of Health; 1995; p. 293-38.
Klein R, Klein BEK, Moss SE.
The Epidemiology of Ocular Problems in Diabetes Mellitus.
In: SS Ferman, editor, Ocular problems in diabetes mellitus.
Boston: Blackwell Scientific Publications; 1992b; p. 1-53.
Klein R, Moss SE, Klein BE.
Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology 1993; 100 (8):1140-6.
Klein R, Moss SE, Klein BE et al.
The Wisconsin epidemiologic study of diabetic retinopathy.
XI.
The incidence of macular edema.
Ophthalmology 1989; 96 (10):1501-10.
Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy.
Results of a prospective randomized study in 50 patients.
Diabete Metab 1991; 17 (1 Pt 2):235-40.
Knowler WC, Barrett-Connor E, Fowler SE et al.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med 2002; 346 (6):393-403.
Koda-Kimble MA, Carlisle BA. Diabetes Mellitus.
In: LY Young; MA Koda-Kimble, editors, Applied therapeutics: the clinical use of drugs.
6th edn. Vancouver: Applied Therapeutics, Inc.; 1995; p. 48-1 to -62.
Kohner EM, Stratton IM, Aldington SJ et al.
Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
Diabet Med 2001; 18 (3):178-84.
Kohner EM, Stratton IM, Aldington SJ et al.
Microaneurysms in the development of diabetic retinopathy (UKPDS 42).
UK Prospective Diabetes Study Group.
Diabetologia 1999; 42 (9):1107-12.
Kouri TT, Viikari JS, Mattila KS et al.
Microalbuminuria.
Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients.
Diabetes Care 1991; 14 (7):591-3.
Kreisberg RA.
Cholesterol-lowering and coronary atherosclerosis: good news and bad news.
Am J Med 1996; 101 (5):455-8.
Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents.
Drug Saf 1994; 11 (4):223-41.
Krolewski AS, Laffel LM, Krolewski M et al.
Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus.
N Engl J Med 1995; 332 (19):1251-5.
Krolewski AS, Warram JH, Freire MB. Epidemiology of late diabetic complications.
A basis for the development and evaluation of preventive programs.
Endocrinol Metab Clin North Am 1996; 25 (2):217-42.
Krumholz HM, Seeman TE, Merrill SS et al.
Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.
Jama 1994; 272 (17):1335-40.
Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus.
Ann Med 1996; 28 (4):341-5.
Lacourciere Y, Belanger A, Godin C et al.
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Kidney Int 2000; 58 (2):762-9.
Laffel LM, McGill JB, Gans DJ.
The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria.
North American Microalbuminuria Study Group.
Am J Med 1995; 99 (5):497-504.
Landstedt-Hallin L, Adamson U, Arner P et al.
Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Diabetes Care 1995; 18 (8):1183-6.
Larme AC, Pugh JA. Attitudes of primary care providers toward diabetes: barriers to guideline implementation.
Diabetes Care 1998; 21 (9):1391-6.
Larpent N, Canivet J. Bicentric evaluation of a teaching and treatment programme for Type 1 (insulin-dependent) diabetic patients.
Diabetologia 1984; 27 (1):62.
Lavery LA, Walker SC, Harkless LB et al.
Infected puncture wounds in diabetic and nondiabetic adults.
Diabetes Care 1995; 18 (12):1588-91.
Lazarus JM, Bourgoignie JJ, Buckalew VM et al.
Achievement and safety of a low blood pressure goal in chronic renal disease.
The Modification of Diet in Renal Disease Study Group.
Hypertension 1997; 29 (2):641-50.
Lee ET, Lee VS, Kingsley RM et al.
Diabetic retinopathy in Oklahoma Indians with NIDDM.
Incidence and risk factors.
Diabetes Care 1992; 15 (11):1620-7.
Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane Review).
The Cochrane Library, Issue 2.
Oxford: Update Software.
2000.
Levey AS. JASN 2000; Vol 11; abstract - A0828.
Lewis EJ, Hunsicker LG, Bain RP et al.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
The Collaborative Study Group.
N Engl J Med 1993; 329 (20):1456-62.
Lewis EJ, Hunsicker LG, Clarke WR et al.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med 2001; 345 (12):851-60.
Life with diabetes.
A series of teaching outlines.
2nd ed: The American Diabetes Association, University of Michigan, Diabetes Research and Training Center.
Available at http://merchant.diabetes.org/adabooks; 2000.
Lindholm LH, Ibsen H, Dahlof B et al.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002; 359 (9311):1004-10.
Lindstrom T, Nystrom FH, Olsson AG et al.
The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus.
Diabet Med 1999; 16 (10):820-6.
Litzelman DK, Slemenda CW, Langefeld CD et al.
Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus.
A randomized, controlled trial.
Ann Intern Med 1993; 119 (1):36-41.
Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
Cochrane Database Syst Rev 2001; 1.
Lucas MJ, Leveno KJ, Williams ML et al.
Early pregnancy glycosylated hemoglobin, severity of diabetes, and fetal malformations.
Am J Obstet Gynecol 1989; 161 (2):426-31.
Lustman PJ, Griffith LS, Freedland KE et al.
Cognitive behavior therapy for depression in type 2 diabetes mellitus.
A randomized, controlled trial.
Ann Intern Med 1998; 129 (8):613-21.
Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Clin Ther 2000; 22 (10):1151-68; discussion 49-50.
Malone JI, Morrison AD, Pavan PR et al.
Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial.
Diabetes Care 2001; 24 (3):522-6.
Manson JE, Nathan DM, Krolewski AS et al.
A prospective study of exercise and incidence of diabetes among US male physicians.
Jama 1992; 268 (1):63-7.
Marchioli R, Marfisi RM, Carinci F et al.
Meta-analysis, clinical trials, and transferability of research results into practice.
The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
Arch Intern Med 1996; 156 (11):1158-72.
Marre M, Chatellier G, Leblanc H et al.
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
Bmj 1988; 297 (6656):1092-5.
Marre M, Hallab M, Billiard A et al.
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.
J Cardiovasc Pharmacol 1991; 18 Suppl 2:S165-8.
Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor.
Am J Health Syst Pharm 1996; 53 (19):2277-90; quiz 336-7.
Mason RP, Kosoko O, Wilson MR et al.
National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies.
Part I. Prevalence findings.
Ophthalmology 1989; 96 (9):1363-8.
Mayfield JA, Reiber GE, Nelson RG et al.
Do foot examinations reduce the risk of diabetic amputation? J Fam Pract 2000; 49 (6):499-504.
Mayfield JA, Reiber GE, Nelson RG et al.
A foot risk classification system to predict diabetic amputation in Pima Indians.
Diabetes Care 1996; 19 (7):704-9.
Mayfield JA, Reiber GE, Sanders LJ et al.
Preventive foot care in people with diabetes.
Diabetes Care 1998; 21 (12):2161-77.
McGlynn Margaret, Senior Vice President of Merk-Medco Managed Care Inc.
Outcomes Study Review.
Testimony before the Senate Special Committee on Aging, March 28, 1996.
Medical nutrition across the continuum of care.
Chicago, IL: The American Dietetic Association; 1998.
Meeting the standards manual for the american diabetes association.
Chicago, IL: The American Diabetes Assocation; 1998.
Meier JL, Swislocki AL, Lopez JR et al.
Reduction in self-monitoring of blood glucose in persons with type 2 diabetes results in cost savings and no change in glycemic control.
Am J Manag Care 2002; 8 (6):557-65.
Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type II diabetes.
Ann Pharmacother 1996; 30 (2):158-64.
Mensing C, Boucher J, Cypress M, et al.
National standards for diabetes self-management education.
Task Froce to Review and Revise the National Standards for Diabetes Self-Management Education Programs.
Diabetes Care 2000; 23(5):682-9.
Merlo J, Ranstam J, Liedholm H et al.
Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study.
Bmj 1996; 313 (7055):457-61.
Merritt GJ, Kobernus CA, Hall NJ et al.
Outcome analysis of a diabetic education clinic.
Mil Med 1983; 148 (6):545-7.
Miller CK, Edwards L, Kissling G et al.
Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial.
Prev Med 2002; 34 (2):252-9.
Miller E, Hare JW, Cloherty JP et al.
Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers.
N Engl J Med 1981; 304 (22):1331-4.
Miller LV, Goldstein J. More efficient care of diabetic patients in a county-hospital setting.
N Engl J Med 1972; 286 (26):1388-91.
Mitchell-Funnel M. A core curriculum for diabetes education.
3rd ed: American Association of Diabetes Educators; 1998.
Mitrakou A, Tountas N, Raptis AE et al.
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Diabet Med 1998; 15 (8):657-60.
Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy.
Kidney Int 1987; 31 (2):673-89.
Mogensen CE, Neldam S, Tikkanen I et al.
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
Bmj 2000; 321 (7274):1440-4.
Monk A, Barry B, McClain K et al.
Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus.
International Diabetes Center.
J Am Diet Assoc 1995; 95 (9):999-1006; quiz 7-8.
Morisaki N, Watanabe S, Kobayashi J et al.
Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study.
J Am Geriatr Soc 1994; 42 (2):142-5.
Moses R, Slobodniuk R, Boyages S et al.
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care 1999; 22 (1):119-24.
Muirhead N, Feagan BF, Mahon J et al.
The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial.
Curr Ther Res 1999; 60:650-60.
Murray J. Microalbuminuria in Type II Diabetes.
Endocrine Practice 1996; 2:211-14.
Nakagami T, Kawahara R, Hori S et al.
Glycemic control and prevention of retinopathy in Japanese NIDDM patients.
A 10-year follow-up study.
Diabetes Care 1997; 20 (4):621-2.
Nakamura T, Ushiyama C, Shimada N et al.
Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.
J Diabetes Complications 2000; 14 (5):250-4.
Nathan DM, Fogel HA, Godine JE et al.
Role of diabetologist in evaluating diabetic retinopathy.
Diabetes Care 1991; 14 (1):26-33.
Nathan DM, McKitrick C, Larkin M et al.
Glycemic control in diabetes mellitus: have changes in therapy made a difference? Am J Med 1996; 100 (2):157-63.
National Diabetes Advisory Board, National Standards for Diabetes Patient Education Programs.
Diabetes Care 1993; 7:xxxi-xxxv.
National High Blood Pressure Education Program Workin Group.
Report on HTN in Diabetes.
Hypertension 1994; 23 (2):152.
National Standards for Diabetes Self-Management Education Programs and American Diabetes Association Review Criteria.
Diabetes Care 1998; 21:S1.
Nauck M, Kramer-Guth A, Bartens W et al.
Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996; 46 (5):319-25.
NCEP ATP II 1993.
See summary of the second report of the National Cholesterol Education Program.
NCEP III.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
Jama 2001; 285 (19):2486-97.
Nelson RG, Newman JM, Knowler WC et al.
Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians.
Diabetologia 1988; 31 (10):730-6.
Nelson RG, Pettitt DJ, Knowler WC et al.
Prediabetic blood pressure and familial predisposition to renal disease in Pima Indians with non-insulin-dependent diabetes mellitus.
J Diabetes Complications 1995; 9 (4):212-4.
Nielsen S, Dollerup J, Nielsen B et al.
Losartan reduces albuminuria in patients with essential hypertension.
An enalapril controlled 3 months study.
Nephrol Dial Transplant 1997; 12 Suppl 2:19-23.
Norris SL, Lau J, Smith SJ et al.
Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control.
Diabetes Care 2002a; 25 (7):1159-71.
Norris SL, Nichols PJ, Caspersen CJ et al.
Increasing diabetes self-management education in community settings.
A systematic review.
Am J Prev Med 2002b; 22 (4 Suppl):39-66.
Norris SL, Engelgau M, Narayan K. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials.
Diabetes Care 2001; (3):561-87.
O'Donnell MJ, Rowe BR, Lawson N et al.
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
J Hum Hypertens 1993; 7 (4):333-9.
Ohkubo Y, Kishikawa H, Araki E et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract 1995; 28 (2):103-17.
Oki JC, Flora DL, Isley WL. Frequency and impact of SMBG on glycemic control in patients with NIDDM in an urban teaching hospital clinic.
Diabetes Educ 1997; 23 (4):419-24.
Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy.
J Am Coll Cardiol 2002; 39 (2):315-22.
Orchard TJ, Strandness DE, Jr.
Assessment of peripheral vascular disease in diabetes.
Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association 18-20 September 1992, New Orleans, Louisiana.
Diabetes Care 1993; 16 (8):1199-209.
Ordonez JD, Hiatt RA.
Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population.
Nephron 1989; 51 (4):524-9.
Padgett D, Mumford E, Hynes M et al.
Meta-analysis of the effects of educational and psychosocial interventions on management of diabetes mellitus.
J Clin Epidemiol 1988; 41 (10):1007-30.
Pahor M, Psaty BM, Alderman MH et al.
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.
Lancet 2000; 356 (9246):1949-54.
Palmberg P, Smith M, Waltman S et al.
The natural history of retinopathy in insulin-dependent juvenile-onset diabetes.
Ophthalmology 1981; 88 (7):613-8.
Pan XR, Li GW, Hu YH et al.
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.
The Da Qing IGT and Diabetes Study.
Diabetes Care 1997; 20 (4):537-44.
Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia 1987; 30 (3):123-31.
Parving HH, Lehnert H, Brochner-Mortensen J et al.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med 2001; 345 (12):870-8.
Pascale RW, Wing RR, Butler BA et al.
Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes.
Diabetes Care 1995; 18 (9):1241-8.
A PBM-Map guideline for the pharmacological management of hyperlipidemia.
Veterans Health Administration.
Diabetes Mellitus Working Group.
Available at http://www.ddppm.med.va.gov 1997.
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation.
Basis for prevention.
Diabetes Care 1990; 13 (5):513-21.
Pedersen TR, Olsson AG, Faergeman O et al.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).
Circulation 1998; 97 (15):1453-60.
Perry JE, Ulbrecht JS, Derr JA et al.
The use of running shoes to reduce plantar pressures in patients who have diabetes.
J Bone Joint Surg Am 1995; 77 (12):1819-28.
Perry TL, Mann JI, Lewis-Barned NJ et al.
Lifestyle intervention in people with insulin-dependent diabetes mellitus (IDDM).
Eur J Clin Nutr 1997; 51 (11):757-63.
The pharmacological treatment of hyperglycemia in NIDDM.
American Diabetes Association.
Diabetes Care 1995; 18 (11):1510-8.
Pharmacy Benefits Management--Medical Advisory Panel (PBM-MAP).
The pharmacologic management of hypertension.
VHA PBM-SHG Publication No. 96-0003.
Hines, IL: harmacy Benefits Management Strategic Health Group, Veterans Health Administration, Department of Veterans Affairs; 1999.
Physicians Desk Reference 1999.
Montvale, NJ: Medical Economics Co.; 1999.
Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes.
The European Study Group of HOE 901 in type 1 diabetes.
Diabetes Care 2000; 23 (2):157-62.
Piette JD, Glasgow RE. Education and Home Glucose Monitoring.
In: H Gerstein; RB Haynes, editors, Evidence-Based Diabetes Care.
Ontario, CA: BC Decker, Inc.; 2001; p. 207-51.
Ponssen HH, Elte JW, Lehert P et al.
Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Clin Ther 2000; 22 (6):709-18.
Post CABG Trial.
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
The Post Coronary Artery Bypass Graft Trial Investigators.
N Engl J Med 1997; 336 (3):153-62.
Pyorala K, Pedersen TR, Kjekshus J et al.
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease.
A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care 1997; 20 (4):614-20.
Pyorala K, Steiner G. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence.
Ann Med 1996; 28 (4):357-62.
Rabb MF, Gagliano DA, Sweeney HE. Diabetic retinopathy in blacks.
Diabetes Care 1990; 13 (11):1202-6.
Rachmani R, Levi Z, Slavachevski I et al.
Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus--a randomized prospective study.
Diabet Med 2002; 19 (5):385-92.
Raji A, Gomes H, Beard JO et al.
A randomized trial comparing intensive and passive education in patients with diabetes mellitus.
Arch Intern Med 2002; 162 (11):1301-4.
Ramsay LE, Haq IU, Jackson PR et al.
The Sheffield table for primary prevention of coronary heart disease: corrected.
Lancet 1996b; 348 (9036):1251.
Ramsay LE, Haq IU, Jackson PR et al.
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.
Lancet 1996a; 348 (9024):387-8.
Rao G. Diagnostic yield of screening for type 2 diabetes in high-risk patients: a systematic review.
J Fam Pract 1999; 48 (10):805-10.
Raskin P, Guthrie RA, Leiter L et al.
Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
Diabetes Care 2000; 23 (5):583-8.
Raskin P, Rendell M, Riddle MC et al.
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Diabetes Care 2001; 24 (7):1226-32.
Ratner RE, Hirsch IB, Neifing JL et al.
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes.
U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
Diabetes Care 2000; 23 (5):639-43.
Ravid M, Ravid D. ACE inhibitors in elderly patients with hypertension.
Special considerations.
Drugs Aging 1996; 8 (1):29-37.
Ravid M, Savin H, Jutrin I et al.
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Ann Intern Med 1993; 118 (8):577-81.
Reiber GE, Boyko EJ, Smith D. Lower extremity foot ulcers and amputations in diabetes.
NIH Publication No. 95-1468.
In: MI Harris; CC Cowie; MP Stern et al., editors, Diabetes in America.
2nd edn. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995; p. 409-27.
Reichard P, Nilsson BY, Rosenqvist U.
The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.
N Engl J Med 1993; 329 (5):304-9.
Relimpio F, Pumar A, Losada F et al.
Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
Diabet Med 1998; 15 (12):997-1002.
Report of the task force on the delivery of diabetes self-management education and medical nutrition therapy.
American Diabetes Task Force, April 21, 1998.
Rickheim PL, Weaver TW, Flader JL et al.
Assessment of group versus individual diabetes education: a randomized study.
Diabetes Care 2002; 25 (2):269-74.
Riddle MC. Tactics for type II diabetes.
Endocrinol Metab Clin North Am 1997; 26 (3):659-77.
Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone.
Glimepiride Combination Group.
Diabetes Care 1998; 21 (7):1052-7.
Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting.
A prospective evaluation of simple screening criteria.
Diabetes Care 1992; 15 (10):1386-9.
Robinson AC, Burke J, Robinson S et al.
The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Diabetes Care 1998; 21 (5):701-5.
Roca-Cusachs A. Lowering blood pressure.
How far, how fast? Drugs 1993; 46 Suppl 2:8-14; discussion -5.
Rodby RA, Rohde RD, Sharon Z et al.
The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy.
The Collaborative Study Group.
Am J Kidney Dis 1995; 26 (6):904-9.
Romero R, Salinas I, Lucas A et al.
Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors.
Diabetes Care 1993; 16 (4):597-600.
Rose B, editor Up To Date in Medicine Wellesley, MA; 1999.
Rosenstock J, Schwartz SL, Clark CM, Jr., et al.
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Diabetes Care 2001; 24(4):631-636.
Rosenstock J, Brown A, Fischer J et al.
Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Diabetes Care 1998; 21 (12):2050-5.
Rosenstock J, Einhorn D, Hershon K et al.
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Int J Clin Pract 2002; 56 (4):251-7.
Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens.
U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Diabetes Care 2000; 23 (8):1137-42.
Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care.
J Clin Endocrinol Metab 1998; 83 (8):2635-42.
Rubins HB, Robins SJ, Collins D et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
VA-HIT Trial.
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
N Engl J Med 1999; 341 (6):410-8.
Sacks FM, Pfeffer MA, Moye LA et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events Trial investigators.
N Engl J Med 1996; 335 (14):1001-9.
Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: current status.
Drugs 1999; 57 (5):665-93.
Savage S, Estacio RO, Jeffers B et al.
Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
Proc Assoc Am Physicians 1997; 109 (2):181-9.
Savage S, Estacio RO, Jeffers B et al.
Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM.
Diabetes Care 1996; 19 (11):1243-8.
Scandinavian Simvastatin Survival Study Group (4S).
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet 1994; 344 (8934):1383-9.
Scheen AJ, Lefebvre PJ. Oral antidiabetic agents.
A guide to selection.
Drugs 1998; 55 (2):225-36.
Scheffler RM, Feuchtbaum LB, Phibbs CS.
Prevention: the cost-effectiveness of the California Diabetes and Pregnancy Program.
Am J Public Health 1992; 82 (2):168-75.
Schlundt DG, Rea MR, Kline SS et al.
Situational obstacles to dietary adherence for adults with diabetes.
J Am Diet Assoc 1994; 94 (8):874-6, 9; quiz 7-8.
Schmid H, Schaan B, Cecconello F et al.
Proliferative diabetic retinopathy is related to cardiovascular autonomic neuropathy in non-insulin-dependent diabetes mellitus.
Diabetes Res Clin Pract 1995; 29 (3):163-8.
Schrier R, editor Renal and Electrolyte Disorders Boston, MA: Little, Brown and Company; 1976.
Schwab SJ, Christensen RL, Dougherty K et al.
Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.
Arch Intern Med 1987; 147 (5):943-4.
Schwartz S, Raskin P, Fonseca V et al.
Effect of troglitazone in insulin-treated patients with type II diabetes mellitus.
Troglitazone and Exogenous Insulin Study Group.
N Engl J Med 1998; 338 (13):861-6.
Self-management education programs and american diabetes association review criteria.
Diabetes Care 1999; 22 (S1):111-14.
Shepherd J, Cobbe SM, Ford I et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
West of Scotland Coronary Prevention Study Group.
N Engl J Med 1995; 333 (20):1301-7.
Sikka R, Waters J, Moore W et al.
Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes.
Diabetes Care 1999; 22 (1):1-6.
Sims DS, Jr., Cavanagh PR, Ulbrecht JS. Risk factors in the diabetic foot.
Recognition and management.
Phys Ther 1988; 68 (12):1887-902.
Singer DE, Nathan DM, Fogel HA et al.
Screening for diabetic retinopathy.
Ann Intern Med 1992; 116 (8):660-71.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.
Arch Intern Med 1997; 157 (21):2413-46.
Sommer A, Tielsch JM, Katz J et al.
Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans.
The Baltimore Eye Survey.
Arch Ophthalmol 1991; 109 (8):1090-5.
Soneru IL, Agrawal L, Murphy JC et al.
Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
Diabetes Care 1993; 16 (6):896-901.
Sparano N, Seaton TL. Troglitazone in type II diabetes mellitus.
Pharmacotherapy 1998; 18 (3):539-48.
Sperduto RD, Hiller R, Chew E et al.
Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study.
Ophthalmology 1998; 105 (5):765-71.
State of Maine.
DHHS reminsbursement pilot study for the ambulatory diabetic education and follow-up (ADEF) program final report.
Augusta, ME, 1983.
Steil CF. Diabetes Mellitus.
In: JT DiPiro; RL Talbert; GC Yee et al., editors, Pharmacotherapy: a pathophysiologic approach.
3rd edn.
New York: Elsevier, Appleton 
Stone NJ. Management of Lipids in Clinical Practice: Profesional Communications, Inc.; 1997.
Stratton IM, Kohner EM, Aldington SJ et al.
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
Diabetologia 2001; 44 (2):156-63.
Stumvoll M, Nurjhan N, Perriello G et al.
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
N Engl J Med 1995; 333 (9):550-4.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Jama 1993; 269 (23):3015-23.
Sweany AE, Shapiro DR, Tate AC et al.
Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus.
NIDDM Study Group.
Clin Ther 1995; 17 (2):186-203.
Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance.
Diabetes Care 2001; 24 (4):619-24.
Take charge of your diabetes.
3rd ed: Available at http://www.cdc.gov/diabetes/pubs/tcyd/index.htm.
Tamas G, Marre M, Astorga R et al.
Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
Diabetes Res Clin Pract 2001; 54 (2):105-14.
Tatti P, Pahor M, Byington RP et al.
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.
Diabetes Care 1998; 21 (4):597-603.
Tielsch JM, Katz J, Quigley HA et al.
Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey.
Ophthalmology 1995; 102 (1):48-53.
Tielsch JM, Katz J, Sommer A et al.
Family history and risk of primary open angle glaucoma.
The Baltimore Eye Survey.
Arch Ophthalmol 1994; 112 (1):69-73.
Tielsch JM, Sommer A, Katz J et al.
Racial variations in the prevalence of primary open-angle glaucoma.
The Baltimore Eye Survey.
Jama 1991; 266 (3):369-74.
Toto RD, Kirk KA, Coresh J et al.
Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study.
J Am Soc Nephrol 1997; 8 (2):279-87.
Travis T. Patient perceptions of factors that affect adherence to dietary regimens for diabetes mellitus.
Diabetes Educ 1997; 23 (2):152-6.
Trischitta V, Italia S, Mazzarino S et al.
Comparison of combined therapies in treatment of secondary failure to glyburide.
Diabetes Care 1992; 15 (4):539-42.
Tuomilehto J, Lindstrom J, Eriksson JG et al.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
New England Journal of Medicine 2001; 344 (18):1343-50.
Uccioli L, Faglia E, Monticone G et al.
Manufactured shoes in the prevention of diabetic foot ulcers.
Diabetes Care 1995; 18 (10):1376-8.
UKPDS 16: Overview of 6 years' therapy of type II diabetes: a progressive disease.
U.K. Prospective Diabetes Study Group.
Diabetes 1995; 44 (11):1249-58.
UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy.
United Kingdom Prospective Diabetes Study Group.
Ann Intern Med 1998; 128 (3):165-75.
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes.
U.K. Prospective Diabetes Study Group.
Diabetes Care 1998; 21 (1):87-92.
UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
UK Prospective Diabetes Study (UKPDS) Group.
Lancet 1998; 352 (9131):837-53.
UKPDS 34: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.
UK Prospective Diabetes Study (UKPDS) Group.
Lancet 1998; 352 (9131):854-65.
UKPDS 38: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes.
UK Prospective Diabetes Study Group.
Bmj 1998; 317 (7160):703-13.
UKPDS 39: efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes.
UK Prospective Diabetes Study Group.
Bmj 1998; 317 (7160):713-20.
US Preventive Services Task Force.
Guide to Clinical Preventive Services.
2nd ed. Baltimore, MD: Williams 
VA/DoD clinical practice guideline for the diagnosis and management of dyslipidemia in the primary care setting.
Available at: http://www.oqp.med.va.gov/cpg/cpg.htm.
VA/DoD clinical practice guideline for the management of diabetes mellitus.
Version 1.0.
Available at: http://www.oqp.med.va.gov/cpg/cpg.htm 1997.
VA/DoD clinical practice guideline for the management of hypertension in the primary care setting.
Available at: http://www.oqp.med.va.gov/cpg/cpg.htm or http://qmo.amedd.army.mil.
VA-HIT Trial, Rubins HB, Robins SJ et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
VA-HIT Trial.
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
N Engl J Med 1999; 341 (6):410-8.
Viberti G, Mogensen CE, Groop LC et al.
Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria.
European Microalbuminuria Captopril Study Group.
Jama 1994; 271 (4):275-9.
Vijan S, Hofer TP, Hayward RA.
Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.
Jama 2000; 283 (7):889-96.
Vijan S, Hofer TP, Hayward RA.
Estimated benefits of glycemic control in microvascular complications in type 2 diabetes.
Ann Intern Med 1997; 127 (9):788-95.
Vivian EM, Goebig ML.
Slowing the progression of renal disease in diabetic patients.
Ann Pharmacother 2001; 35 (4):452-63.
Walker JD, Bending JJ, Dodds RA et al.
Restriction of dietary protein and progression of renal failure in diabetic nephropathy.
Lancet 1989; 2 (8677):1411-5.
Wang F. Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas.
Formulary 1998; 33:409-23.
Waugh HV, Addlesee AJ.
A prototype model for renal vasculature and its application in haemodialyser miniaturization.
Proc Inst Mech Eng [H] 1997; 211 (6):479-82.
Weir GC, Nathan DM, Singer DE. Standards of care for diabetes.
Diabetes Care 1994; 17 (12):1514-22.
What I need to know about eating and diabetes.
Available at http://www.ndic@info.niddk.nih.gov or from National Diabetes Clearing House (301-654-3327).
Whiting MJ, Shephard MD, Tallis GA. Measurement of plasma LDL cholesterol in patients with diabetes.
Diabetes Care 1997; 20 (1):12-4.
Wieland LD, Vigil JM, Hoffman RM et al.
Relationship between home glucose testing and hemoglobin Alc in type II diabetes patients.
Am J Health Syst Pharm 1997; 54 (9):1062-5.
Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
Diabet Med 1999; 16 (9):755-61.
Wilson PW, D'Agostino RB, Levy D et al.
Prediction of coronary heart disease using risk factor categories.
Circulation 1998; 97 (18):1837-47.
Wolf GL, Wilson SE, Cross AP et al.
Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial.
Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199.
J Vasc Interv Radiol 1993; 4 (5):639-48.
Wolffenbuttel BH, Gomis R, Squatrito S et al.
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Diabet Med 2000; 17 (1):40-7.
Wolffenbuttel BH, Landgraf R.
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes.
Dutch and German Repaglinide Study Group.
Diabetes Care 1999; 22 (3):463-7.
Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ et al.
Comparison of different insulin regimens in elderly patients with NIDDM.
Diabetes Care 1996; 19 (12):1326-32.
Wright A, Burden AC, Paisey RB et al.
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Diabetes Care 2002; 25 (2):330-6.
Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes.
HOE 901/3002 Study Group.
Diabetes Care 2000; 23 (8):1130-6.
Yki-Jarvinen H, Kauppila M, Kujansuu E et al.
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.
N Engl J Med 1992; 327 (20):1426-33.
Yki-Jarvinen H, Ryysy L, Nikkila K et al.
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus.
A randomized, controlled trial.
Ann Intern Med 1999; 130 (5):389-96.
Young MJ, Cavanagh PR, Thomas G et al.
The effect of callus removal on dynamic plantar foot pressures in diabetic patients.
Diabet Med 1992; 9 (1):55-7.
Zeller K, Whittaker E, Sullivan L et al.
Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus.
N Engl J Med 1991; 324 (2):78-84.
Zimmerman BR, Epenshade J, Fujimoto WF.
The pharmacological treatment of hyperglycemia in NIDDM.
